Motohiko Kato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Motohiko Kato has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Masahiko Tsujii
Osaka University Graduate School of Medicine, Osaka, Japan
21 shared publications- Tetsuo Takehara
Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Japan
21 shared publications - Tsutomu Nishida
Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Japan
19 shared publications - Hideki Iijima
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan
14 shared publications Takuya Yamada
Department of Gastroenterology and Hepatology, Osaka National Hospital, Osaka, Japan
12 shared publicationsYoshito Hayashi
Osaka University Graduate School of Medicine, Osaka, Japan
11 shared publications
Latest Publications
- 14 April 2015
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 82 (1) , 175-177
Localized gastric amyloidosis mimicking a submucosal tumor-like gastric cancer
- 14 April 2015
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 82 (1) , 175-177
Localized gastric amyloidosis mimicking a submucosal tumor-like gastric cancer
- 20 January 2015
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 47 (S 01) , E39-E40
Polyglycolic acid sheets for repair of refractory esophageal fistula
Gastrointestinal fistulas have been treated endoscopically with various devices, but endoscopic management is occasionally difficult [1]. Here we report a case of refractory esophageal fistula successfully closed using polyglycolic acid (PGA) sheets. A 61-year-old man with superficial carcinoma in the midthoracic esophagus was referred to our hospital. Endoscopic submucosal dissection (ESD) was performed with subsequent intralesional steroid injection (triamcinolone acetonide 80 mg) to prevent post-ESD stricture [2]. Histopathological diagnosis of the lesion was squamous cell carcinoma (pT1a-MM, ly0, v0, HM0, VM0) and no additional treatment was performed. The patient complained of dysphagia 35 days after ESD. Endoscopic examination showed moderate stricture ([Fig. 1 a]), and endoscopic balloon dilation was done using the CRE balloon dilator (Boston Scientific Co, Japan). However this resulted in perforation ([Fig. 1 b]) followed by subcutaneous and mediastinal emphysema. Fistula formation was observed 8 days after perforation ([Fig. 2 a]). Conservative management and four attempts at endoscopic clip closure were ineffective. Contrast radiography 44 days after perforation showed pooling of contrast agents in the mediastinum through the fistula. Therefore, we prepared three pieces of PGA sheet (Neoveil; Gunze Co, Japan). These were cut to 4 × 3 mm and stuffed into the fistula ([Fig. 2 b]). Using the PGA as scaffolding, we filled in the gaps with fibrin glue (Bolheal; Astellas Pharma, Japan) ([Fig. 2 c]), and then closed the fistula using endoclips. At 5 days after the procedure, the fistula was seen to be filled with granulation tissue ([Fig. 2 d]), and oral intake was started. The patient was discharged 18 days after the procedure. Neither fistula nor emphysema was observed at follow-up computed tomography (CT) 1 month after the procedure. PGA sheeting has been used to prevent delayed perforation after duodenal or colorectal ESD [3] [4], because it acts as a scaffold for migrating cells, and is absorbed spontaneously. This case suggests a novel further use for PGA sheets in endoscopic therapy. Endoscopy_UCTN_Code_TTT_1AO_2AI
- 20 January 2015
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 47 (S 01) , E39-E40
Polyglycolic acid sheets for repair of refractory esophageal fistula
Gastrointestinal fistulas have been treated endoscopically with various devices, but endoscopic management is occasionally difficult [1]. Here we report a case of refractory esophageal fistula successfully closed using polyglycolic acid (PGA) sheets. A 61-year-old man with superficial carcinoma in the midthoracic esophagus was referred to our hospital. Endoscopic submucosal dissection (ESD) was performed with subsequent intralesional steroid injection (triamcinolone acetonide 80 mg) to prevent post-ESD stricture [2]. Histopathological diagnosis of the lesion was squamous cell carcinoma (pT1a-MM, ly0, v0, HM0, VM0) and no additional treatment was performed. The patient complained of dysphagia 35 days after ESD. Endoscopic examination showed moderate stricture ([Fig. 1 a]), and endoscopic balloon dilation was done using the CRE balloon dilator (Boston Scientific Co, Japan). However this resulted in perforation ([Fig. 1 b]) followed by subcutaneous and mediastinal emphysema. Fistula formation was observed 8 days after perforation ([Fig. 2 a]). Conservative management and four attempts at endoscopic clip closure were ineffective. Contrast radiography 44 days after perforation showed pooling of contrast agents in the mediastinum through the fistula. Therefore, we prepared three pieces of PGA sheet (Neoveil; Gunze Co, Japan). These were cut to 4 × 3 mm and stuffed into the fistula ([Fig. 2 b]). Using the PGA as scaffolding, we filled in the gaps with fibrin glue (Bolheal; Astellas Pharma, Japan) ([Fig. 2 c]), and then closed the fistula using endoclips. At 5 days after the procedure, the fistula was seen to be filled with granulation tissue ([Fig. 2 d]), and oral intake was started. The patient was discharged 18 days after the procedure. Neither fistula nor emphysema was observed at follow-up computed tomography (CT) 1 month after the procedure. PGA sheeting has been used to prevent delayed perforation after duodenal or colorectal ESD [3] [4], because it acts as a scaffold for migrating cells, and is absorbed spontaneously. This case suggests a novel further use for PGA sheets in endoscopic therapy. Endoscopy_UCTN_Code_TTT_1AO_2AI
- Open Access
- 24 September 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 1-7
Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma
Background: Chemoradiotherapy (CRT) is an effective modality for stage I esophageal squamous cell carcinoma (ESCC). However, salvage treatments are often required even if complete response (CR) has been achieved. To this end, it is important to accurately diagnose lymph node or other organ metastatic recurrences. Note that lymph node enlargements (except metastatic recurrence) are often detected during the follow-up period after CRT. The purpose of this study was to elucidate the clinical characteristics of lymph node enlargement after CRT. Methods: In this retrospective cohort study, patients diagnosed with stage I (T1 [submucosal invasion] N0M0) ESCC were treated with cisplatin and 5-fluorouracil concurrently with radiotherapy. A total of 55 patients were enrolled in the study from February 2006 to August 2011. Results: The median follow-up period was 46 months. The 3-year overall and progression-free survival rates were 90.7% and 71.2%, respectively, and the CR rate was 87.2% (48/55). Nine of the 48 CR patients were finally diagnosed with recurrences, including 7 lymph node metastases and 2 local recurrences. Lymph node enlargement was initially identified in 20 of the total 55 patients during the follow-up; 9 patients were finally diagnosed with lymph node recurrence, whereas 11 patients had benign reactive lymph node enlargement. Conclusion: The present study demonstrated the high incidence of enlarged lymph nodes after CRT for stage I ESCC. It is important to accurately distinguish between benign lymph node enlargement and recurrent lymph nodes to avoid unnecessary salvage treatments.
- 24 September 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 1-7
Open AccessLymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma
Background: Chemoradiotherapy (CRT) is an effective modality for stage I esophageal squamous cell carcinoma (ESCC). However, salvage treatments are often required even if complete response (CR) has been achieved. To this end, it is important to accurately diagnose lymph node or other organ metastatic recurrences. Note that lymph node enlargements (except metastatic recurrence) are often detected during the follow-up period after CRT. The purpose of this study was to elucidate the clinical characteristics of lymph node enlargement after CRT. Methods: In this retrospective cohort study, patients diagnosed with stage I (T1 [submucosal invasion] N0M0) ESCC were treated with cisplatin and 5-fluorouracil concurrently with radiotherapy. A total of 55 patients were enrolled in the study from February 2006 to August 2011. Results: The median follow-up period was 46 months. The 3-year overall and progression-free survival rates were 90.7% and 71.2%, respectively, and the CR rate was 87.2% (48/55). Nine of the 48 CR patients were finally diagnosed with recurrences, including 7 lymph node metastases and 2 local recurrences. Lymph node enlargement was initially identified in 20 of the total 55 patients during the follow-up; 9 patients were finally diagnosed with lymph node recurrence, whereas 11 patients had benign reactive lymph node enlargement. Conclusion: The present study demonstrated the high incidence of enlarged lymph nodes after CRT for stage I ESCC. It is important to accurately distinguish between benign lymph node enlargement and recurrent lymph nodes to avoid unnecessary salvage treatments.
- 1 May 2014
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 79 (5) , AB144
449 Midterm Outcomes of Non-Curative ESD for Early Gastric Cancer: a Multicenter Retrospective Study by the Osaka Gut Forum
- 1 May 2014
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 79 (5) , AB144
449 Midterm Outcomes of Non-Curative ESD for Early Gastric Cancer: a Multicenter Retrospective Study by the Osaka Gut Forum
- 25 April 2014
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 46 (08) , 680-684
Esophageal submucosal dissection under steady pressure automatically controlled endoscopy (SPACE): a clinical feasibility study
Background and study aims: Steady pressure automatically controlled endoscopy (SPACE) is a new insufflation system that provides constant carbon dioxide (CO2) insufflation pressure during prolonged procedures. The system consists of an overtube, a surgical insufflator, and a newly developed leak-proof valve. The aims of this study were to validate the feasibility and safety of SPACE for esophageal endoscopic submucosal dissection (ESD). Patients and methods: This was a clinical phase I trial, involving 10 patients who underwent esophageal ESD. The primary end point was the rate of adverse events within 30 days (grade 0 to 4). Secondary end points were changes in partial pressure of carbon dioxide (PaCO2) and vital signs during ESD, completion rate of ESD, and degree of abdominal distension by patient assessment and radiographic grading. Results: All adverse events were Grade 2 or less. Mild PaCO2 elevation after ESD was noted; however, no associated symptoms were reported. The procedure was completed under SPACE alone in 8 of 10 patients. Minimal post-procedural bowel distension was observed. Conclusions: In this small pilot study, SPACE was feasible and appeared to be safe. Further study with larger case numbers is required to demonstrate efficacy and safety. Clinical trial registration: UMIN000005434
- 25 April 2014
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 46 (08) , 680-684
Esophageal submucosal dissection under steady pressure automatically controlled endoscopy (SPACE): a clinical feasibility study
Background and study aims: Steady pressure automatically controlled endoscopy (SPACE) is a new insufflation system that provides constant carbon dioxide (CO2) insufflation pressure during prolonged procedures. The system consists of an overtube, a surgical insufflator, and a newly developed leak-proof valve. The aims of this study were to validate the feasibility and safety of SPACE for esophageal endoscopic submucosal dissection (ESD). Patients and methods: This was a clinical phase I trial, involving 10 patients who underwent esophageal ESD. The primary end point was the rate of adverse events within 30 days (grade 0 to 4). Secondary end points were changes in partial pressure of carbon dioxide (PaCO2) and vital signs during ESD, completion rate of ESD, and degree of abdominal distension by patient assessment and radiographic grading. Results: All adverse events were Grade 2 or less. Mild PaCO2 elevation after ESD was noted; however, no associated symptoms were reported. The procedure was completed under SPACE alone in 8 of 10 patients. Minimal post-procedural bowel distension was observed. Conclusions: In this small pilot study, SPACE was feasible and appeared to be safe. Further study with larger case numbers is required to demonstrate efficacy and safety. Clinical trial registration: UMIN000005434
- 28 January 2014
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 46 (06) , 499-502
A novel endoscopic submucosal dissection technique with robust and adjustable tissue traction
Background and study aims: A novel esophageal endoscopic submucosal dissection (ESD) technique was devised using a newly developed overtube to achieve adequate tissue traction. The aim of this study was to evaluate the feasibility and safety of this new full-traction ESD (tESD) technique. Methods: The key feature of tESD is tissue traction by grasping forceps, which is passed through the built-in side channel of the overtube. The strength and direction of traction is controlled by rotating the overtube and by adjusting its depth. The en bloc resection rate, procedure time, adverse events, and dissected area per minute were evaluated in a porcine model (n = 10) and compared with those of conventional ESD (n = 10). Results: tESD provided robust and adjustable tissue traction during the procedure. En bloc resection was accomplished in all lesions with no complications. Median procedure time was similar to that of the conventional technique (25 vs. 27 minutes; P = 0.4723) but the submucosal injection catheter was used less often (1.5 vs. 6; P < 0.01). Conclusions: tESD might contribute to more efficient esophageal ESD by providing adequate tissue traction. This inexpensive technique may become an attractive option in esophageal ESD. * These authors contributed equally to this work.
- 28 January 2014
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 46 (06) , 499-502
A novel endoscopic submucosal dissection technique with robust and adjustable tissue traction
Background and study aims: A novel esophageal endoscopic submucosal dissection (ESD) technique was devised using a newly developed overtube to achieve adequate tissue traction. The aim of this study was to evaluate the feasibility and safety of this new full-traction ESD (tESD) technique. Methods: The key feature of tESD is tissue traction by grasping forceps, which is passed through the built-in side channel of the overtube. The strength and direction of traction is controlled by rotating the overtube and by adjusting its depth. The en bloc resection rate, procedure time, adverse events, and dissected area per minute were evaluated in a porcine model (n = 10) and compared with those of conventional ESD (n = 10). Results: tESD provided robust and adjustable tissue traction during the procedure. En bloc resection was accomplished in all lesions with no complications. Median procedure time was similar to that of the conventional technique (25 vs. 27 minutes; P = 0.4723) but the submucosal injection catheter was used less often (1.5 vs. 6; P < 0.01). Conclusions: tESD might contribute to more efficient esophageal ESD by providing adequate tissue traction. This inexpensive technique may become an attractive option in esophageal ESD. * These authors contributed equally to this work.
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Sa1720 Loss of p53 Function of Cancer Cells Activates Fibroblasts Leading to Tumor Progression in Colon Cancer
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Sa1720 Loss of p53 Function of Cancer Cells Activates Fibroblasts Leading to Tumor Progression in Colon Cancer
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB153
496 Next Generation Esophageal ESD Under Steady Pressure Automatically Controlled Endoscopy (SPACE): a Clinical Feasibility Study
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB153
496 Next Generation Esophageal ESD Under Steady Pressure Automatically Controlled Endoscopy (SPACE): a Clinical Feasibility Study
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB188-AB189
Sa1392 “Tornado ESD”: a Novel Endoscopic Technique With Robust and Adjustable Tissue Traction
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB188-AB189
Sa1392 “Tornado ESD”: a Novel Endoscopic Technique With Robust and Adjustable Tissue Traction
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB344
Su1490 Esophageal Endoscopic Submucosal Dissection Using in Combination With Scissors-Type Device
- 1 May 2013
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 77 (5) , AB344
Su1490 Esophageal Endoscopic Submucosal Dissection Using in Combination With Scissors-Type Device